Krystal Biotech (NASDAQ:KRYS) Insider Sells $7,702,750.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $301.00 on Monday. The stock has a market cap of $8.87 billion, a PE ratio of 40.24 and a beta of 0.53. The firm has a 50-day moving average of $282.39 and a 200-day moving average of $264.58. Krystal Biotech, Inc. has a 52-week low of $127.99 and a 52-week high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the company. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after acquiring an additional 481,200 shares in the last quarter. Norges Bank bought a new position in Krystal Biotech in the fourth quarter valued at about $70,159,000. William Blair Investment Management LLC boosted its stake in shares of Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after purchasing an additional 227,038 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Krystal Biotech by 2,078.9% during the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after purchasing an additional 209,369 shares in the last quarter. Finally, UBS Group AG increased its stake in shares of Krystal Biotech by 970.8% in the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after buying an additional 177,922 shares during the period. Institutional investors own 86.29% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on KRYS. Wolfe Research began coverage on Krystal Biotech in a research note on Friday, March 27th. They issued a “peer perform” rating for the company. Jefferies Financial Group lifted their target price on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Chardan Capital boosted their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $324.11.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.